Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.14 USD
Change Today +0.0135 / 10.59%
Volume 116.1K
ILIU On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

interleukin genetics inc (ILIU) Key Developments

Interleukin Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2015

Interleukin Genetics, Inc. reported earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $403,212 against $487,566 a year ago. Loss from operations was $1,692,564 against $1,666,512 a year ago. Loss from continuing operations before income taxes was $1,843,195 against $1,664,519 a year ago. Loss from continuing operations was $1,843,195 against $1,664,519 a year ago. Net loss was $1,843,195 or $0.01 basic and diluted net loss per common share against $1,664,519 or $0.01 basic and diluted net loss per common share a year ago. The change in total revenue is largely attributable to a decrease in the company’s genetic test kits returned for processing related to the company’s sales through Access Business Group’s promotional product bundle program.

Interleukin Genetics, Inc., Q1 2015 Earnings Call, May 15, 2015

Interleukin Genetics, Inc., Q1 2015 Earnings Call, May 15, 2015

Interleukin Genetics, Inc. Announces Management Changes

Interleukin Genetics, Inc. announced the appointment of Mark B. Carbeau as chief executive officer and director. Dr. KennethS. Kornman, DDS, PhD, who served as the president and CEO since August 2012, will continue to serve as president, chief scientific officer and a director. Mr. Carbeau is a transformative healthcare leader who brings to Interleukin more than three decades of business expertise in the life science industries, with a proven track record of building high growth diagnostic and pharmaceutical businesses. Prior to joining company Mr. Carbeau was co-founder and CEO of Diagnostyx.

Interleukin Genetics and Employee Benefit Consulting Group LLC Partner to Expand Awareness and Adoption of PerioPredict

Interleukin Genetics, Inc. and Employee Benefit Consulting Group LLC (EBCG) announced the signing of a collaboration agreement to help expand knowledge and potential coverage for Interleukin's novel genetic risk test, PerioPredict®. PerioPredict® is an innovative, easy-to-use tool that identifies individuals with a higher risk of progressing to severe periodontal disease. This collaboration was formed to leverage the rapidly growing field of genetic testing as part of an approach to more effective overall healthcare management. Predictive genetic tests identify genetic variations that may affect a patient's risk of developing a certain disease, thus enabling the patient and the healthcare professional to engage in more aggressive preventative care, and assist with treatment decisions. PerioPredict® works by measuring variations in the genes for Interleukin-1 (IL-1), a key mediator of inflammation, and identifies individuals at increased risk for more severe periodontal disease, also known as periodontitis or gum disease. Under the terms of this strategic collaboration, Interleukin and EBCG will work together to build awareness of PerioPredict® as a powerful tool for personalizing patient care among insurance carriers, benefit plans and employer groups, and to potentially incorporate the test in the design of risk-based benefit plans.

Interleukin Genetics, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Interleukin Genetics, Inc. announced earnings results for the fourth quarter and full year ended December 31, 2014. The company’s revenues for the quarter ended December 31, 2014, were $322,000, compared to $671,000 for the same period in 2013. This decrease is primarily attributable to less breakage revenue (deferred revenue recognized when, after the passage of time, test redemption is considered unlikely) and license fee income recognized in 2014 compared the same period in 2013. These decreases are largely due to the recognition in the quarter ended December 31, 2013 of breakage revenue from test kit sales made in the years ended December 31, 2009 and 2010, and of license fee income for the quarters ended June 30, September 30, and December 31, 2013, whereas breakage revenue and license fee income recognized in the quarter ended December 31, 2014 related to that quarter only. Net loss for the quarter ended December 31, 2014, was $1.6 million, or $0.01 per basic and diluted common share, compared to $1.9 million or $0.02 per basic and diluted common share for the same period in 2013. Loss from operations was $1,626,959 or $0.01 per basic and diluted share against $1,912,138 or $0.02 per basic and diluted share a year ago. Loss from continuing operations before income taxes was $1,637,783 against $1,903,985 a year ago. The company’s revenues for the year ended December 31, 2014, were $1.8 million, compared to $2.4 million for the year ended December 31, 2013. The change in total revenue is attributable to higher revenues in 2013 due to a promotion by Interleukin’s partner, Amway, resulting in a larger volume of pre-paid test kits returned for processing, partially offset by $309,348 of breakage revenue recognized in the year ended December 31, 2014, compared to $213,233 of breakage revenue recognized in the year ended December 31, 2013. In addition, Interleukin earned $150,923 of royalties for the year ended December 31, 2014, from its license agreement with ABGI, compared to $198,960 of royalties earned in the year ended December 31, 2013. The net loss for the year ended December 31, 2014, was $6.3 million, or $0.05 per basic and diluted common share, compared to a net loss of $7.1 million, or $0.08 per basic and diluted common share for 2013. Loss from operations was $6,329,399 or $0.05 per basic and diluted share against $6,598,526 or $0.08 per basic and diluted share a year ago. Loss from continuing operations before income taxes was $6,335,714 against $7,057,933 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILIU:US $0.14 USD +0.0135

ILIU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ILIU.
View Industry Companies
 

Industry Analysis

ILIU

Industry Average

Valuation ILIU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.8x
Price/Book 7.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERLEUKIN GENETICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.